Intellia Therapeutics Presents Additional Positive Clinical and Patient-Reported Data for Lonvoguran Ziclumeran at ACAAI 2026
Intellia Therapeutics Completes Enrollment in Phase 3 MAGNITUDE-2 Trial of Nexiguran Ziclumeran for Patients with Hereditary Transthyretin Amyloidosis with Polyneuropathy
Intellia Therapeutics Announces Upcoming Lonvoguran Ziclumeran Investor Event and Seven Presentations at ACAAI 2026
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran for Hereditary Angioedema
Intellia Therapeutics to Hold Conference Call on August 6 to Discuss Second Quarter 2026 Financial Results and Business Updates
Intellia Therapeutics Reports Additional Positive Phase 3 Results for Lonvoguran Ziclumeran in Patients with Hereditary Angioedema
Intellia Therapeutics to Report Additional Phase 3 HAELO Data for Lonvoguran Ziclumeran in Late-Breaking Oral Presentation at EAACI 2026
Michael Gentile Announces Filing of Early Warning Report Related to Acquisition of Common Shares of Cascadia Minerals Ltd.